VKTX

Viking Therapeutics, Inc.

A clinical-stage biopharmaceutical company in San Diego that develops experimental drugs for metabolic and endocrine disorders, including obesity. Its lead candidate, VK2735, is a dual GLP-1/GIP receptor agonist being tested as both a weekly injection and a daily pill for weight loss. Founded in 2012 by Brian Lian, a former Wall Street biotech analyst, the company built its early pipeline by licensing programs from Ligand Pharmaceuticals.